A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Published:2014-01-23 Issue:3 Volume:73 Page:595-604
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Chiorean E. Gabriela,Sweeney Christopher,Youssoufian Hagop,Qin Amy,Dontabhaktuni Aruna,Loizos Nick,Nippgen Johannes,Amato Robert

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2389-9.pdf

Reference43 articles.

1. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–1316

2. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B (1993) Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90:393–397

3. Ostman A (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15:275–286

4. Dong J, Grunstein J, Tejada M et al (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23:2800–2810

5. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD (2007) PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 104:524–528

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The reactive stroma response regulates the immune landscape in prostate cancer;Journal of Translational Genetics and Genomics;2024-07-24

2. A Complete Sojourn of Monoclonal Antibodies: AI, Rare Diseases / Disorders and Immunotoxic Effects;Current Proteomics;2024-06

3. Current approaches in glioblastoma multiforme immunotherapy;Clinical and Translational Oncology;2024-03-21

4. Therapeutic Monoclonal Antibodies against Cancer: Present and Future;Cells;2023-12-14

5. Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties;Scientific Reports;2023-09-06